To continue reading this article, subscribe for FREE to
Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.
Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.
NOTTINGHAM, U.K.—Looking to expand its enzyme operations, Novozymes acquired Delta Biotechnology from the sanofi-aventis group. The new company, Novozymes Delta, will continue to operate as a self-contained business unit, developing and manufacturing recombinant proteins using engineered proprietary yeast strains.
"Novozymes will set the direction and has the resources that will enable us to further progress our yeast-based protein expression capabilities to the benefit of our global customer base," said Dermot Pearson, commercial operations director of Novozymes Delta. "The market for safe, animal-free recombinant proteins is growing and, with Novozymes backing us, we'll be in a great position to satisfy this market".
Novozymes Delta will also license its technology to pharmaceutical, healthcare and biotechnology partner companies as customized solutions, offering it a strong position in the industrial enzymes market. According to a July 2005 report by Freedonia Group, this market hit $3.7 billion and was expected to grow at 6.5 percent a year to 2009.
This person does not yet have a bio.View Full Profile
